Scientists hunt for clues to predict who benefits from head and neck cancer immunotherapy
NCT ID NCT04603248
First seen Feb 13, 2026 · Last updated May 23, 2026 · Updated 17 times
Summary
This study aims to find immune-related markers in blood and tumor tissue that can predict how well patients with recurrent or metastatic head and neck cancer respond to the drug nivolumab. Researchers will analyze samples from 50 adults who have already tried platinum chemotherapy. The goal is to better identify which patients are most likely to benefit from this treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Yonsei Severance Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.